COVID-19, Flu and RSV Shots − An Epidemiologist Explains Why All Three Matter This Fall
Epidemiologist Annette Regan explains why officials recommend that people get these shots over the coming months.
Tag: vaccine RSV
All
Latest
All
Latest
Most Pregnant Women Open to RSV Vaccine to Protect Infants, Survey Finds
A nationwide survey revealed that 54% of individuals who are pregnant or trying to become pregnant are interested in the RSV vaccine.
All
Latest
CDC Endorses Pfizer’s Maternal RSV Vaccine to Shield Newborns
Members of the Advisory Committee on Immunization Practices voted 11-1 to recommend the maternal RSV vaccine for pregnant people to prevent RSV lower respiratory tract infection in infants.Â
CDC Recommends GSK, Pfizer RSV Vaccines For Older Adults
The CDC is recommending use of two new RSV vaccines from GSK and Pfizer for people ages 60 years and older.
Read More
FDA Approves Pfizer’s RSV Vaccine
The FDA approved Abrysvo for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years and older.Â
Read More
FDA Approves First RSV Vaccine
In clinical trials, the vaccine significantly reduced the risk of developing RSV-associated lower respiratory tract disease by 82.6% and reduced the risk of developing severe RSV-associated lower respiratory tract disease by 94.1% in adults age 60 and older.
Read More
Canada Approves RSV Immunization for Infants
The single-dose antibody drug can be used in babies during their first RSV season and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Read More
Janssen Ceases Development of RSV Vaccine for Adults
Janssen had been enrolling participants in a phase 3 trial to demonstrate the efficacy of its RSV vaccine candidate in adults age 60 and older.
Read More
Five RSV Articles for the Week
FDA panel favors approval for two RSV vaccines, ‘Tripledemic’ hits US households, and a monoclonal antibody may be ready for next season—here are five RSV stories you should check out this week.
Read MoreSingle-Dose RSV Shot for Infants Could Be Ready for Next Season
The target action date for the FDA’s approval decision is set for the third quarter. If approved, nirsevimab is expected to be available in the US for the 2023/2024 RSV season.
Read More
Moderna RSV Vaccine 83% Effective, Gets ‘Breakthrough’ Label from FDA
Phase 3 data found the Moderna RSV vaccine was 83.7% effective against RSV-associated lower respiratory tract disease in adults age 60 and older. The FDA has granted the vaccine a Breakthrough Therapy Designation.
Read More
FDA Panel to Convene to Review Promising RSV Vaccine Candidates
The FDA accepted Biologics License Applications and granted priority review for both Pfizer and GSK’s RSV older adult vaccine candidates last year following positive data from phase 3 trials.Â
Read More
RSV Surge Hits Children’s Hospitals
As flu season picks up and experts weigh concerns about another possible COVID surge, children’s hospitals are already filling with patients with another viral threat: respiratory syncytial virus, or RSV.Â
Read More
Study: Efficacy of RSV Vaccine in Adults
The bivalent prefusion F respiratory syncytial virus (RSVpreF) vaccine is effective against symptomatic RSV infection and viral shedding, new research in the New England Journal of Medicine found.
Read More
Positive Phase III Data for GSK RSV Vaccine Candidate
A phase III trial investigating the GSK RSV vaccine candidate for adults aged 60 years and above exceeded its primary endpoint with no unexpected safety concerns observed, the company announced.
Read More